How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

594 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Androgenetic alopecia as an early marker of benign prostatic hyperplasia. (PubMed)

Androgenetic alopecia as an early marker of benign prostatic hyperplasia. Androgenetic alopecia (AGA) and benign prostatic hyperplasia are both androgen-dependent entities that respond to the blocking of 5-alpha-reductase.The objective of this study was to determine whether prostatic volumes and urinary flow changes were higher in patients with early-onset AGA than in healthy control subjects.This was an observational case-control study of 87 men: 45 with early-onset AGA diagnosed

2011 Journal of American Academy of Dermatology

142. Brain-derived nerve factor and neurotrophins in androgenetic alopecia. (PubMed)

Brain-derived nerve factor and neurotrophins in androgenetic alopecia. Several growth factors and cytokines have been shown to be involved in normal hair cycling as well as in androgenetic alopecia (AGA). However, the molecular cascades in AGA downstream from androgen receptor activation are far from being fully elucidated.We sought to determine the difference in the protein expression of growth factors/cytokines in balding vs. nonbalding scalp specimens from the same individuals affected (...) (P < 0·001). Expression of neurotrophin-3 and of β-nerve growth factor was also upregulated. On the other hand, protein expression of insulin-like growth factor-1 and its binding proteins as well as of the vascular endothelial growth factor family were significantly downregulated in the balding scalp.Neurotrophic factors, especially BDNF, may be important in mediating the effects of androgens on hair follicles, serving as a negative regulatory control signal. Further studies may lead to novel

2011 British Journal of Dermatology

143. Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2013 Clinical Trials

144. Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2013 Clinical Trials

145. Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01942837 Recruitment Status : Active, not recruiting First Posted : September 16, 2013

2013 Clinical Trials

146. GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01918306 Recruitment Status : Terminated (company stopped

2013 Clinical Trials

147. Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women

Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Androgen Excess (...) for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 32 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Study Start Date : April 2013 Estimated Primary Completion Date : June 30, 2022 Estimated Study Completion Date : June 30, 2022 Resource links provided

2013 Clinical Trials

148. New Treatment for Seborrheic Alopecia: The Ligature of the Arteries of the Scalp (Full text)

New Treatment for Seborrheic Alopecia: The Ligature of the Arteries of the Scalp Bilateral ligature of the superficial temporal arteries and of the posterior auricular arteries is proposed as a treatment for seborrheic alopecia. The arterial circulatory dynamics are, thus, replaced by capillary circulatory dynamics. Hypoxia is produced which inhibits enzymatic systems and lessens nocuous action of androgen and lipid factors on the pilosebaceous effectors. The histologic study shows

1977 Journal of the National Medical Association PubMed

149. Obliteration of Alopecia by Hair-Lifting: A New Concept and Technique (Full text)

for tonsure baldness in men and even in the skull-cap type of androgenic alopecia in women. (...) Obliteration of Alopecia by Hair-Lifting: A New Concept and Technique A new concept and technique of treatment of male-pattern alopecia are described. The concept is to remove, in serial stages, segments of skin that measure about 3 cm by 7 to 10 cm from the bald area of an alopecic scalp, and to raise the remaining hairy portion into the previously bald area.The technique consists of undermining the skin in the normal plane of cleavage between the galea and the sub-aponeurotic loose connective

1977 Journal of the National Medical Association PubMed

150. Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. (Full text)

Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. The gene encoding the androgen receptor (AR) is associated with male pattern baldness (androgenetic alopecia - AGA). In case-control and family analyses, we mapped AR and the adjacent intergenic regions. We found evidence for association with two independent loci, one upstream and previously described and the other downstream and apparently novel. The haplotype comprising these SNPs

2010 Experimental Dermatology PubMed

151. A comparative study of dyslipidaemia in men and woman with androgenic alopecia. (Full text)

A comparative study of dyslipidaemia in men and woman with androgenic alopecia. Several studies have analyzed the relationship between androgenetic alopecia and cardiovascular disease (mainly heart disease). However few studies have analyzed lipid values in men and women separately. This case-control study included 300 patients consecutively admitted to an outpatient clinic, 150 with early onset androgenetic alopecia (80 males and 70 females) and 150 controls (80 males and 70 females (...) ) with other skin diseases. Female patients with androgenic alopecia showed significant higher triglycerides values (123.8 vs 89.43 mg/dl, p = 0.006), total cholesterol values (196.1 vs 182.3 mg/dl, p = 0.014), LDL-C values (114.1 vs 98.8 mg/dl, p = 0.0006) and lower HDL-C values (56.8 vs 67.7 mg/dl, p <0.0001) versus controls respectively. Men with androgenic alopecia showed significant higher triglycerides values (159.7 vs 128.7 mg/dl, p = 0.04) total cholesterol values (198.3 vs 181.4 mg/dl, p = 0.006

2010 Acta Dermato-Venereologica PubMed

152. Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia

Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01052870 Recruitment Status : Completed First

2010 Clinical Trials

153. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. (Full text)

hyperandrogenism and idiopathic hirsutism.A multicenter prevalence survey included 592 consecutive premenopausal women (393 from Madrid, Spain and 199 from Bologna, Italy) reporting spontaneously for blood donation. Immediately before donation, we conducted clinical and biochemical phenotyping for androgen excess disorders. We determined the prevalence of (i) hirsutism, acne and alopecia as clinical signs of androgen excess and (ii) functional disorders of androgen excess, including PCOS, defined (...) by the National Institute of Child Health and Human Development/National Institute of Health criteria, idiopathic hyperandrogenism and idiopathic hirsutism.Regarding clinical signs of hyperandrogenism, hirsutism and acne were equally frequent [12.2% prevalence; 95% confidence interval (CI): 9.5-14.8%], whereas alopecia was uncommon (1.7% prevalence, 95% CI: 0.7-2.7%). Regarding functional disorders of androgen excess, PCOS and idiopathic hirsutism were equally frequent (5.4% prevalence, 95% CI: 3.6-7.2

2012 Human Reproduction PubMed

154. Androgen actions on the human hair follicle: perspectives. (Full text)

Androgen actions on the human hair follicle: perspectives. Androgens stimulate beard growth but suppress hair growth in androgenetic alopecia (AGA). This condition is known as 'androgen paradox'. Human pilosebaceous units possess enough enzymes to form the active androgens testosterone and dihydrotestosterone. In hair follicles, 5α-reductase type 1 and 2, androgen receptors (AR) and AR coactivators can regulate androgen sensitivity of dermal papillae (DP). To regulate hair growth, androgens (...) stimulate production of IGF-1 as positive mediators from beard DP cells and of TGF-β1, TGF-β2, dickkopf1 and IL-6 as negative mediators from balding DP cells. In addition, androgens enhance inducible nitric oxide synthase from occipital DP cells and stem cell factor for positive regulation of hair growth in beard and negative regulation of balding DP cells. Moreover, AGA involves crosstalk between androgen and Wnt/β-catenin signalling. Finally, recent data on susceptibility genes have provided us

2012 Experimental Dermatology PubMed

155. Alopecia

variant of lichen planopilaris. Etiology The alopecias comprise a large group of disorders with multiple and varying etiologies ( ). The most common cause of alopecia is Androgenetic alopecia (male-pattern or female-pattern hair loss) Androgenetic alopecia is an androgen-dependent hereditary disorder in which dihydrotestosterone plays a major role. This form of alopecia may eventually affect up to 80% of white men by the age of 70 (male-pattern hair loss) and about half of all women (female-pattern (...) Alopecia Alopecia - Dermatologic Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Diagnostic Tests for Skin Disorders Which

2013 Merck Manual (19th Edition)

156. Pharmacogenomic Study of Androgenetic Alopecia

Collaborator: Chang Gung Memorial Hospital Information provided by: Taipei Medical University WanFang Hospital Study Details Study Description Go to Brief Summary: Androgenic alopecia, the common form of hair loss is a highly heritable disorder of considerable social significance affecting around 40% of adult men and women. A variety of genetic and environmental factors are likely to play a role in androgenetic alopecia. Genetic variants in the human androgen receptor gene (AR) have been reported (...) in a yet-to-be-identified androgen-independent pathway. The total number of evaluated patients with androgenic alopecia will be at least 300. All patients will be further grouped as good responders or poor responders to conventional medications, such as topical minoxidil and systemic finasteride. Candidate genes potentially involved in gout and its treatment response will be selected from the published literatures; specifically, two resources of candidate genes will be selected: (i) genes which

2010 Clinical Trials

157. Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

: 0.1mg dutasteride Drug: 0.5mg dutasteride Drug: Finasteride placebo Drug: Dutasteride placebo Phase 3 Detailed Description: Androgenetic alopecia is a common, androgen-induced, pattern of progressive loss of scalp hair with an onset at any age after puberty in genetically predisposed people. The influence of androgens on scalp hair growth is mediated by local and systemic conversion of testosterone to dihydrotestosterone , by the enzyme 5 alpha-reductase. 5 alpha-reductase has been shown to exist (...) at Baseline with those obtained at Week 12. This assessment was made separately based on the global photography of the vertex and frontal views. The change from Baseline in hair growth was assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased. Number of Participants With the Indicated Change From Baseline (BL) in the Stage (S) of Androgenic Alopecia

2010 Clinical Trials

158. Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

for eligibility information Ages Eligible for Study: 18 Years to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Males with moderate male-pattern baldness (androgenic alopecia) Females with moderate female pattern hair loss Non-smoker or smoker with at least 30 days abstinence from smoking/using nicotine-containing products Exclusion Criteria: Any dermatological condition of the scalp other than androgenic alopecia (males) or female pattern hair loss (...) Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2010 Clinical Trials

159. Female Pattern Hair Loss in Complete Androgen Insensitivity Syndrome. (PubMed)

Female Pattern Hair Loss in Complete Androgen Insensitivity Syndrome. Female pattern hair loss, also known as female androgenetic alopecia, is generally regarded as an androgen-dependent disorder representing the female counterpart of male balding. We describe female pattern hair loss occurring in a patient with complete androgen insensitivity syndrome suggesting that mechanisms other than direct androgen action contribute to this common form of hair loss in women.

2010 British Journal of Dermatology

160. Androgenic alopecia and insulin resistance: are they really related? (PubMed)

Androgenic alopecia and insulin resistance: are they really related? Androgenic alopecia is known to be androgen-dependent. Insulin is found in hair follicles and may play a role in the regulation of androgen metabolism and the hair-growth cycle.To compare the insulin resistance between people with androgenic alopecia and a control group.A case-control study was conducted with 97 cases in the patient and 87 in the control group. Serum fasting insulin level, fasting blood glucose, serum total (...) cholesterol, triglyceride and high-density lipoprotein (HDL) were all measured in both groups.There was no difference in serum fasting insulin level, fasting blood glucose, serum total cholesterol, triglyceride, HDL and insulin resistance between the two groups (P > 0.05).Despite previous reports suggesting a link, our study found no significant relationship between insulin resistance and androgenic alopecia. Further studies are warranted.

2009 Clinical and experimental dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>